316 filings
Page 6 of 16
8-K
2nd dz37c863878d
13 Jul 20
Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study
8:33am
EFFECT
xtiv5opnf65 k9
6 Jul 20
Notice of effectiveness
12:15am
UPLOAD
n1nwn
1 Jul 20
Letter from SEC
12:00am
CORRESP
pzk84l8
1 Jul 20
Correspondence with SEC
12:00am
CORRESP
rynh wqar
1 Jul 20
Correspondence with SEC
12:00am
8-K
oxf47 9p847a2wvjeso
12 Jun 20
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
3jcu4t8mv
20 May 20
Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock
4:04pm
424B5
td42ag1nkebunz9
20 May 20
Prospectus supplement for primary offering
4:03pm
424B5
rncdn3
20 May 20
Prospectus supplement for primary offering
4:02pm
424B5
wj8jz2vfwrp7gxu
18 May 20
Prospectus supplement for primary offering
4:02pm
8-K
c32 ozriwjgqooii
11 May 20
Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results
4:03pm
8-K
m2ddxa
11 May 20
Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19
8:29am
DEFA14A
y7gp3sypltuhfe
27 Apr 20
Additional proxy soliciting materials
4:31pm
8-K
wb6c 68txk3ocbod3iq
8 Apr 20
Other Events
8:31am
8-K
o1s04i4xgwshn90che
6 Apr 20
Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
8:32am
NT 10-K
difa53uctbnh5y wu
31 Mar 20
Notice of late annual filing
4:10pm